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Cytomegalovirus disease is an important cause of 
morbidity following liver transplantation. To date 
there has not been an effective prophylaxis for CMV 
disease after liver transplantation. One hundred forty-
three patients were randomized to receive either high 
dose oral acyclovir (800 mg 4 times a day) alone for a 
months after transplantation <acyclovir group) or in-
travenous ganciclovir (5 mglkg twice a day) for 14 days 
followed by high dose oral acyclovir to complete a 
a-month regimen (ganciclovir group). Of 139 patients 
available for evaluation, 43 of 71 (61%) patients from 
the acyclovir group developed CMV infection com-
pared with 16 of 68 (24%) from the ganciclovir group 
(relative risk. 3.69; 95% confidence interval. 2.07-6.56; 
P<O.OOOOl). Of those randomized, CMV disease was 
seen in 20 (28%) of the acyclovir group compared with 
6 (9%) of the gancielovir group <relative risk. 5.11; 95% 
confidence interval, 2.05-12.75; P=O.OOOl). The median 
time to onset of CMV infection was 45 days in the acy-
clovir group compared with 78 days in the ganciclovir 
group (P=O.OO4). The median time to onset of CMV 
disease was 40 days in the acyclovir group compared 
with 78 days in the ganciclovir patients (P=O.02). 
With respect to primary CMV infection, there was no 
difference in the rates in the 2 groups, but tissue in-
vasive disease and recurrent CMV disease were less 
frequent in the ganeiclovir group. It is concluded that 
a course of 2 weeks of ganciclovir immediately after 
transplantation followed by high dose oral acyclovir 
for 10 weeks is superior to a 12-week course of high 
dose oral acyclovir alone for prevention of both CMV 
infection and CMV disease after liver transplanta-
tion. However, the lack of significant effect in sero-
negative recipients who received grafts from sero-
positive donors suggests that other strategies are 
needed to prevent CMV infection in this high risk 
population. 
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Cytomegalovirus remains a major cause of infectious 
morbidity after solid organ or bone marrow transplantation 
(l-J), Increased utilization of liver transplantation as the 
preferred option for patients with end-stage liver disease has 
led to the recognition of the importance of this viral infection 
and its profound effect on the clinical course. allograft dys-
function. and length of hospital stay of the transplant recipi-
ent (4-6). 
Treatment of CMV disease in immunosuppressed recipi-
ents poses special problems. Current antiviral therapy sup-
presses CMV but may fail to cure it. and infection often 
relapses after treatment is stopped. Although these phenom-
ena may still occur even with CMV prophylaxis, most cases of 
CMV disease occur within a predictably constant time period 
after transplantation. usually the first 2 months, which 
makes effective prophylaxis a clinically useful measure. The 
precise frequency and severity of CMV infection depends on 
a number of factors, the most important of which include the 
native CMV immune status of the recipient, the transmission 
of the virus from the donor organ, and the nature and inten-
sity of immunosuppression \ 7-10). 
Various methods have been investigated to prevent CMV 
disease after organ transplantation. EnhanCing the immune 
response by vaccination or by passive immunization haa re-
duced the incidence of CMV disease in renal transplant re-
cipients (11, 12). Though passive administration of a high 
titer CMV immunoglobulin has been reported recently to 
reduce the incidence of CMV disease and associated mortal-
ity after liver transplantation, it was not commercially avail-
able when this trial was perfonned ( 13), Despite the lack of 
therapeutic activity against CMV, high dose intravenous or 
oral acyclovir has been reported to prevent CMV disease in 
renal and bone marrow transplant patients without adverse 
effects on patient or graft survival <14, 15). Although no 
similar prospective trials have been reported in liver trans-
plant recipients, an uncontrolled study showed no decrease in 
CMV disease with high dose oral acyclovir. In contrast, a 
i-week course of ganciciovir followed by high dose oral acy-
clovir for 3 months reduced the rate of CMV disease but did 
not eliminate it (16). J Department of Anesthesiology/Critical Care Medicine, 
, DiviSIOn of Gastroenterology. 
\ School of Pharmacy. 
6 Departments of Medicine and Pathology. 
7 Division of Infectious Diaeue. 
In this prospective randomized trial. we compared the ef-
ficacy and safety of a sequential courae of ganciclovir and 
high dose acyclovir with high dose acyclovir alone for the 
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prevention of CMV disease in a population of adult patients 
undergoing liver transplantation. 
MATERIALS AND METHODS 
Randomizatwn and study protocol. This prospective randomized 
trial was conducted at the University of Pittsburgh Medical Center 
after approval by the Committee on the Use of Human Subjects in 
Research. Recipients who were at least 18 years of age were eligible 
for participation. Patients with fulminant hepatic failure. and/or 
stage 3 or 4 hepatic coma and those patients with underlying hepatic 
malignancies who received preoperative chemotherapy were ex-
cluded so as to minimize potential additive toxicities. 
Although a placebo arm would have been desirable. it was consid-
ered unethical. Since ganciclovir is a potent inhibitor of CMV. using 
it for more than 1 week should suppress CMV for a longer period of 
time. Despite the lack of an established regimen for CMV prophy-
laxis in liver transplantation at the time of the trial. and the clear 
differences between liver and kidney transplantation. it was thought 
that all patients should receive at least high dose acyclovir. the 
prophylactic regimen demonstrated to be useful in renal transplant 
recipients. 
Once informed consent was obtained. patients were assigned to be 
started on either acyclovir or ganciclovir according to a fixed-block 
randomization scheme (block size = 4). No initial stratification for 
CMV risk factors was done. 
Acyclovir (Burroughs Wellcome Co. Research Triangle Park, NC) 
was provided in 200-mg capsules with the initial dose given in the 
intensive care unit by nasogastric tube. Subsequent oral dose adjust-
ments were based on the patient's estimated creatinine clearance 
rate as follows: > 80 ml/min, 800 mg 4 times daily; 50-79 mllmin, 800 
mg 3 times daily; 10-50 mllmin. 800 mg twice daily; and < 10 mlImin, 
800 mg once daily. 
Ganciclovir (Syntex, Palo Alto. CAl was administered intrave-
nously for 14 days in a dose adjusted to the estimated creatinine 
clearance rate: > 80 mlImin, 5 mglkg twice daily; 50-79 mllmin, 2.5 
mgikg twice daily; 10-50 mllmin. 2.5 mgikg once daily; < 10 mlImin, 
1.25 mgikg once daily. Patients then received 10 weeks of high dose 
oral acyclovir to complete 12 weeks of therapy. Initiation of either 
drug was done to allow for stabilization of both patient and graft 
function within 48 hr. 
Our analysis addressed the period from study entry to 24 weeks, 
which encompassed the initial 12 weeks of prophylaxis and a subse-
quent 12-week follow-up period to allow for the detection of CMV 
infection and disease occurring late and to assess the effects of treat-
ment on early patient and graft survival. 
Clinical management and immunosuppression. Patients under-
went OLT according to the standard procedure at the University of 
Pittsburgh (7). Biliary tract anastomosis was done either by chole-
dochocholedochostomy, or Roux-en-Y choledochojejunostomy. Initial 
immunosuppression protocols included FK506 (Fujisawa Pharma· 
ceuticals. Osaka. Japan) or CsA (Sandoz. East Hanover, NJ) as de-
scribed prevIOusly ( 18). Subsequent adjustments of immunosuppres· 
sive dose were dictated by the quality of the graft, the presence of 
rejection. and the plasma levels and/or toxicity of FK506 or CsA. 
Rejection episodes were treated by 1 g of methylprednisolone and/or 
a 5-day taper from 200 mg to 20 mg. If necessary. OKT3 (Ortho 
Pharmaceuticals, Raritan. NJ) was used to treat steroid-resistant 
rejection. None of the patients received either standard immuno-
globulin or CMV hyperimmune globulin. 
Weekly clinical and laboratory evaluations. including virologic 
studies. were done for 3 months. and then at monthly intervals for 6 
months. In addition. patients were evaluated twice weekly during 
any subsequent hospital admission. Any signs or symptoms sugges-
tive of CMV infection (e.g., fever. headaches, malaise. myalgia) or 
findinp localized to the liver.lunga, gastrointeatinal tract. or central 
nervous system were recorded and appropriate inveRiptiona _re 
carried out. 
Laboratory tests. At the time of enrollment. the following indices 
were measured: hemoglobin level and hematocrit, platelet, reticulo-
cyte, and differential white blood cell counts; serum creatinine and 
blood urea nitrogen; and serum aminotransferases, alkaline phos-
phatase, total bilirubin, and albumm. 
Virologic and serologic studies. Donor and recipient CMV IgG and 
IgM antibody titers were measured on all patients by a semiauto-
mated immunofluorescence test (FlAX test system; Whittaker Bio-
products, Inc .• Waltersville. MOl. Only 2 donor sera were not tested. 
IgG CMV antibody titers > 20 were considered positive. IgM CMV 
antibody was reported as negative, equivocal, or positive. Serum 
samples for antibodies to CMV and specimens from urine, throat 
swabbing, and blood buffy coat were cultured for CMV by conven-
tional cell culture methods and by shell·vial assay for early CMV 
antigen detection (19). Weekly samples for CMV cultures and serol-
ogy were taken during the first 3 months after transplantation, and 
monthly samples were taken for 3 more months. Additional cultures 
and serum samples were taken during any subsequent hospital ad-
mission or clinical illness. 
Definitions and study endpoints. The primary endpoints of this 
study were the development of CMV disease or death. The protocol 
drugs were withdrawn if symptomatic CMV infection developed or if 
toxic reactions occurred. 
Primary CMV infection was defined by either seroconveraion. a 
positive shell-vial assay, or the isolation of virus in a cultured speci-
men from any site in a patient who was seronegative before trans-
plantation. Only 1 patient seroconverted without a positive culture. 
To exclude the effect of passively transfused antibodies, we used only 
sera collected more than 30 days after transplantation to document 
changes in antibody titer. Secondary CMV infection included either 
reactivation or reinfection and was diagnosed by isolation of virus 
from any site in a seropositive recipient. CMV disease or sympto-
matic CMV infection was defined by the following: CMV viral syn-
drome. localized invasive CMV disease. or disseminated CMV dis-
ease. The diagnosis of CMV viral syndrome required laboratory 
documentation of CMV infection along with fever> 3SDC for 2 or 
more days in the absence of another cause. combined with one of the 
following findings: atypical lymphocytosis > 3%; white blood cell 
count < 4.000/mm3; or platelets < lOO.OOO/mmJ. Localized CMV dis-
ease was defined as tissue invasion in a single organ determined 
histopa~ologically and/or by isolation of virus from a tissue speci-
men. Dlssemmated CMV disease was defined as invasive involve-
ment of 2 or more tissues at noncontiguous sites. 
Statistical methods. The total sample size was calculated to allow 
the ~etection of a .50% reduction in CMV infection among the ganci-
dOVlr·treated patients. assuming an infection rate of 60%, an alpha 
error of 0.05 (two-sided), and a beta error of 0.20. Time to CMV 
infection and CMV disease was calculated from the date of trans-
plantsti~n to the date of infection and disease, respectively. The 
cumul.atlve rau: of CMV infection and the cumulative rate of aymp-
tomauc CMV mfectlon were estimated using the Kaplan.Meier 
method (20). These rates were then plotted for patient estimate. of 
the infection·free and CMV disease-free in both acyclovir and ganci-
dovir groups. 
Comparison between the incidence of CMV infection and disease 
in both treatment groups was made using Cox's proportional hazards 
model. as was the univariate and multivariate analyaia of risk fac-
tors for CMV infection and CMV disease. Relative risk of CMV in-
fection and disease was computed and 95% confidence interval was 
generated via Cox's regression. The factors analyzed included age, 
type of CMV prophylaxis. donor and recipient serolOgic status, blood 
products transfused. number of rejection episodes, number of steroid 
boluses, OKT3 therapy, United Network of Organ Sharing (UNOS)· 
classification, and the type of bile tract anastomosis. The likelihood 
ratio chi·square test was used to asses the risk of each factor for CMV 
• Abbreviations: FFP, fresh-frozen pluma; UNOS, United Net-
work of Orpa Sharing. 
October 1994 MARTIN ET AL. 
781 
infection and CMV disease. Based on the results of these univariate 
analyses. we then performed a multivariate analysis. Variables were 
chosen to be included in the multivariate analysis if they had a 
P-value < 0.25. The backward elimination method was used as a 
variable selection technique using the likelihood ratio chi-square test 
as a means to assess each factor. Variables were entered or excluded 
from the model based on a P-value for entry of 0.10 and a P-value for 
exclusion of 0.15. Both pretransplant donor-recipient serology and 
UNOS classification were analyzed as indicator variables using 
negative-donor/negative-recipient serologic status and UNOS classi-
fication of 2 as reference categories. Approximate 95% confidence 
intervals were generated for each relative risk. 
Baseline characteristics of the patient population were compared 
between the 2 groups using the standard two-sample t test for con-
tinuous data and the Pearson chi-square test for categorical data. All 
tests of significance were two-tailed. A P-value of 0.05 or less was 
considered to indicate statiatical significance. 
RESULTS 
Patient enrollment and randomization. Between Febru-
ary 1, 1991, and August 31, 1991, 143 patients were enroll~d 
in the study. Four patients were excluded from final analysls 
for the following reasons: active CMV infection at the time of 
enrollment (1 patient), death from bacterial sepsis and mul-
tiorgan failure at 2 weeks and 3 weeks, respectively (2 pa-
tients). and failure to receive study drug due to institution of 
early postoperative chemotherapy (1 patient). One patient 
was randomized to ganciclovir but inadvertently received 
acyclovir and was included in the acyclovir analysis. 
Sixty-nine acyclovir group patients (97%) and 62 ganciclo-
vir group patients (91%) took the assigned drug for 12 weeks 
or reached a study endpoint. Eight patients (6%) did not 
complete a full drug protocol, of whom 6 were in the ganci-
clovir group and 2 were in the acyclovir group. One patient 
received 14 days of ganciclovir and failed to receive high dose 
oral acyclovir; two patients completed 14 days of ganciclovir 
and only 1 month of high dose oral acyclovir. Three patients 
had ganciclovir stopped due to neutropenia (1 patient) and 
neurotoxicity (2 patients). In the acyclovir group, 1 patient, 
after only 1 month of acyclovir. was found to have sympto-
matic bilateral iliac artery aneurysms requiring aortofemoral 
bypass. Acyclovir was not resumed after surgery. In another 
patient. acyclovir was stopped due to neurotoxicity. 
Patient characteristics. The final analysis included 139 
patients: 71 in the acyclovir group and 68 in the ganciclovir 
group. The 2 groups were comparable with respect to: age; 
sex; number of transplants received; type of bile tract anas-
tomosis; proportion receiving immunosuppression with 
FK506. CsA. or OKT3; number of rejection episodes and ste-
roid boluses; CMV status of the donor and recipient at the 
time of transplantation; number of units of packed red cells. 
platelets. and fresh-frozen plasma tFFP) received; and UNOS 
classification (Table I\, 
Overall clinical outcome. One-year patient survival was 
83% (79.5% ganciclovir group; 83% acyclovir group), while 
graft survival was 77% (77.5% ganciclovir group; 76.5% acy-
clovir grouP). During the first 6 months after liver transplan-
tation. 59 patients (42%) developed CMV infection. Of these 
patients. 33 remained asymptomatic (56%) while 26 patients 
(44%) developed CMV disease. 
Mortality was not significantly different between the 2 
groups. Thirteen patient. died (9.3%) a median of 42 days 
!, from the time of transplant (range. 32-180 days). Although 
TABLE 1. Demographics and clinical characteristics of patients 
Acyclovir group Ganciclovir group 
(n=71) (n=68) 
Characteristics 
Sex (M/F) 35/36 43125 
Age (mean :: 1 SOl 47:: 12.9 48.1:::13.2 
Previous transplant 1 1 
Choledochocholedochotomy 44 42 
Roux-en-Y choledochojejunostomy 27 26 
UNOS classification 
2 Home 14 15 
3 Hospital 31 26 
4lCU 26 27 
CMV serological status 
Donor/recipient 
Positive/negative 11 7 
Negative/negative 6 7 
PositiveiPositive 30 25 
NegativeiPositive 24 27 
Donor not tested 0 2 
Immunosuppression 
FK506 68 63 
CsA 3 5 
Biopsy-proven rejection epiaodes 
None 27 23 
1 40 39 
>1 5 6 
Additional immunosuppression 
Steroid Bolua 
None 23 19 
1 30 38 
>1 15 14 
OKT3 3 3 
Blood products transfused 
(mean ::!: 1 SOl 
Packed red cells 30.2::28.1 34.8:31 
Platelets 48.9::61.9 50.1:88 
Fresh-frozen plasma 24.1::25.3 28.7::30.1 
not a direct cause of death in any patient. symptomatic CMV 
infection preceded death in 4 of 5 acyclovir group patients 
compared with only 1 of 8 ganciclovir group patients. Causes 
of death included: liver failure (1 patient). bacterial sepsis 
and multisystem organ failure (8 patients). fungal sepsis (1 
patient), accelerated rejection (1 patient), acute myocardial 
infarction (1 patient), and sudden respiratory arrest (1 pa-
tient). Twelve grafts failed (9 in acyclovir group and 3 in 
ganciclovir group) in a median time of 19 days after trans-
plantation (range, 1~O days). All 12 patients subsequently 
underwent retransplantation. 
Comparison of acyclovir and ganciclovir groups on the in-
cidence of CMV infection. A mean number of 34 cultures for 
CMV (range, 12-120) were obtained from each patient. CMV 
was isolated in 43 of 71 acyclovir group patients (61%) com-
pared with 16 of 68 ganciclovir group patients (24%), a sig-
nificant reduction (Table 2). There was no significant differ-
ence in primary CMV infection in groups receiving acyclovir 
TABLE 2. Incidence of asymptomatic and symptomatic CMV 
infection in acyclovir and ganclclovir groups" 
CMV 
infection 
Acyclovir Ganciclovir Relative 
95% CI p group group nsk 
In-71) (n-68) 
Asymptomatic 23 (32%) 10 (15%) 3.24 1.57. 6.66 0.0007 
Symptomatic 20 (2811» 6 (911)) 5.11 2.05. 12.75 0.0001 
• All patient. bad CMV infec:tion but one had positive CMV eul-
au., .. did all patienu with CMV di.Ieaae. 
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alone or ganciclovir followed with acyclovir (65% vs. 50%) 
(Table 3). The greatest effect of early ganciclovir prophylaxis 
was on the reduction of CMV infection in seropositive pa-
tients (secondary infection regardless of donor serology). The 
rate was 59% in the acyclovir group in contrast to 17% in the 
ganciclovir group (Table 3). 
Seroconversion was noted in all but 1 of 12 seronegative 
patients who developed CMV infection. One patient assigned 
acyclovir remained seronegative despite 2 documented epi-
sodes of culture-positive CMV disease. 
Comparison of acyclovir and ganciclovir groups on the in-
cidence of CMV disease. Asymptomatic CMV infection was 
noted in 23 (32%) acyclovir group patients compared with 10 
(15%) ganciclovir group patients (relative risk. 3.24; 
P=O.0007), while CMV disease was seen in 20 (28%) acyclovir 
group patients and 6 (9%) ganciclovir group patients (relative 
risk, 5.11; P=O.OOOI) (Table 2). Although CMV syndrome was 
the most frequent clinical manifestation in both groups, 
striking differences in the patterns of tissue invasive disease 
were noted between the serologic subgroups (Table 4). Local-
ized CMV disease (pneumonitis, hepatitis, or gastrointestinal 
disease) was seen in 11 acyclovir group patients compared 
with 2 ganciclovir group patients. No ganciclovir group pa-
tient developed CMV pneumonia. In contrast, 5 acyclovir 
group patients had CMV pneumonia and all required me-
chanical ventilation. Two such patients subsequently died 
from bacterial (1 patient) or fungal (1 patient) infection, and 
autopsy in these patients failed to demonstrate residual 
CMV disease. Four of 5 patients with CMV hepatitis received 
acyclovir alone. No graft loss could be related directly to CMV 
disease. 
Comparison of acyclovir and ganciclovir groups on the in-
cidence of viremia. VU'emia was noted in a total of 26 CMV-
infected patients (44%). In the patients who developed infec-
tion, CMV was recovered in blood from 37.5% of ganciclovir 
group patients and 46.5% of acyclovir group patients. VU'e-
mia without symptomatic CMV infection was noted in 6 pa-
tients (5 acyclovir group, 1 ganciclovir group), while localized 
disease without viremia was noted in 6 patients (5 acyclovir 
group, 1 ganciclovir group). 
TIming of CMV infection. The median time from trans-
plantation to CMV infection was 45 days (range, 17-151 
days) in the acyclovir group compared with 78 days (range, 
19-144 days) in the ganciclovir group (P=0.004) (Fig. 1). The 
median time to CMV disease was 40 days (range, 19-140 
days) in the acyclovir group compared with 78 days (range, 
54-95 days) in the ganciclovir group (P=0.02) (Fig. 2). 
The median time to primary infection was 39 days (range, 
22-56 days) in the acyclovir group compared with 77 days 
(range, 54-92 days) in the ganciclovir group (P=O.OOO3). The 
median time to secondary infection was 49 days (range, 17-
151 days) in the acyclovir group and 81 days (range, 19-144 
days) in the ganciclovir group (P=O.l). 
Recurrent CMV disease. All patients who subsequently de-
veloped CMV disease in this trial, regardless of study drug 
assignment, were treated with a l4-day course of ganciclovir. 
Five patients, however, developed recurrent CMV disease at 
a median of 101 days (range, 62-203 days) after transplan-
tation and 61 days (range, 36-157 days) after the first epi-
sode of CMV disease. Four of 5 patients with recurrent CMV 
disease belonged to the acyclovir group. In addition, 4 were 
seronegative patients who received seropositive allografts. 
Only 1 seronegative patient who received a seropositive graft 
had recurrent CMV disease in the ganciclovir group. Thus, 
counting initial and recurrent episodes of primary CMV dis-
ease (Table 4), there were 11 episodes in the acyclovir group 
and 5 episodes in the ganciclovir group (NS). These patients 
responded promptly to a second course of ganciclovir. No 
further recurrent CMV disease has been observed at a mini-
mum of I-year follow-up in any patient. 
Risk factors for CMV infection and CMV disease. CMV 
infection and CMV disease result from a complex interplay 
between various possible factors. After screening by univari-
ate analysis of factors listed in Materials and Methods, a 
multivariate Cox regression analysis for CMV infection and 
disease was done. The result was that prophylaxis with acy-
clovir alone (P<O.OOOOI), and donor-seropositive/recipient-
seronegative matches (P<O.007) were risk factors associated 
with CMV infection (Table 5). When CMV disease was con-
sidered, the multivariate analysis demonstrated prophylaxis 
with acyclovir alone (P=O.005) and transfusion of more than 
30 U of packed RBCs (P=O.OI) to be associated with an in-
creased risk for CMV disease. The donor-seropositive/recipi-
ent-seronegative combination demonstrated a borderline sta-
tistical risk for developing CMV disease (P=O.06). 
Risk factors for primary and secondary CMV infection. 
The multivariate Cox proportional hazards model was used 
to analyze the same variables described above while control-
ling for recipient pretransplant serologic status. For sero-
negative recipients, this analysis showed that donor seroposi-
tivity (P=0.006), and the number of units of FFP transfused 
(P=O.04) were associated with infection (Table 6). Neither 
ganciclovir followed by high dose acyclovir nor high dose acy-
clovir alone exerted a protective effect for primary CMV 
infection (P=0.2). 
For seropositive recipients, this analysis showed that pro-
phylaxis with acyclovir alone (P<O.OOOOl) was the sole vari-
able found to be associated with secondary CMV infection. A 
borderline statistical risk for secondary CMV infection was 
noted when the presence of rejection episodes was considered 
(P=0.07). 
Adverse effects. Severe neutropenia (neutrophil count < 
1000/mm3 ) was observed in 1 ganciclovir group patient after 
10 days of therapy. Ganciclovir was discontinued and high 
dose oral acyclovir was begun 3 days later to complete the 
TABLE 3. Incidence of CMV primary and secondary infection in acyclovir and ganciclovir groups" 
CMV 
infection 
Primary infection 
Secondary infection 
Acyclovir GauadoY1r 
group group 
(n-71) (0-68) 
11117 ESS~F 
321M (SK) 
T11KE~F 
9IS2 E1T~F 
Relatiw 
rialt 
1.94 
4.89 
91S ... CI 
0.76.6.03 
2.33,10.27 
p 
0.2 
<0.00001 
• Patienta at "*Arptima,. .. ...,."""", ...... a.a, i F aI.... 0 ....... 8II'OpOGGw for CMV befbre _ Q'lDtatiOll. 
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TABLE 4. Manifestations of CMV disea.se according to pretransplant donor and recipient serology 
Serology Patients 
Acyclovir group (donor/recipient) (n=20) 
POSINEG 11 
POSIPOS 30 
~bdfmlp 24 
;"''EGINEG 6 
71 
Ganciclovir group (donor/recipient) (n=6) 
" POSINEG I 
POSIPOS 25 
NEGIPOS 27 
NEGINEG 7 
66< 
a Median time to first episode of CMV disease. 
b Also gastrointestinal involvement. 
, Two donor serologies were not available. 
c 
~ G.. 
Y 
.. 
:s 
Syndrome 
3 
4 
2 
0 
-
9 
3 
0 
1 
0 
-
4 
> 0.8 i ~ 
............... _ .......... . 
..... : ...... , .................. _-
() ~ _., ••• .1-
o ._.---
>- 0.4 I .. , 
- I .. -. ~ I J 
~ ~f L.. _ ...... "" •• -;""' •• -=K/~~_-•• _: ____ ~_~_-__ - __ ____' 
o 4 8 10 12 14 18 1. 20 22 24 21 
T!me(weekl) 
Ganclclovlr group Acyclovir group 
- ............ . 
FIGURE 1. Probability of developing CMV infection in acyclovir and 
ganclciovir groups. 
3-month regimen. Neurotoxicity was seen in 3 patients in the 
first week after transplantation (2 ganciclovir group patients, 
1 acyciovir group patient). These patients developed confu-
sion and lethargy, with no focal lesions found on neurologic 
evaluation. Prompt improvement was seen after withdrawal 
of treatment drugs and no permanent neurologic sequelae 
have been noted. 
DISCUSSION 
This prospective, randomized trial demonstrates that pro-
phylactic ganciclovir in the early posttransplant period fol-
lowed by high dose acyclovir provides substantial protection 
from CMV infection and disease in adult liver transplant 
recipients without adversely affecting either patient or graft 
survival. In addition, the significant delay to the onset of both 
primary and secondary CMV infection noted in ganciclovir 
patients avoided the critical period when surgical complica-
tions. immunosuppression. and acute rejection were most 
intense. This benefit is further enhanced by the fact that 
CMV infection, even without disease. exerts an immunosup-
pressant effect that increuea the incidence of other opportu-
nistic infections (21 ). 
Pneumonia Hepatitis GI tract Timing" Recurrent diseaBe 
.. 
:: o.a 
GI 
III 
i3 
>o.a ~ () 
2 
1 
2 
0 
-
5 
0 
0 
0 
0 
-
0 
2 
0 
1 
1 
-
5 
0 
0 
0 
1b 
-
1 
0 36 3 
0 75 0 
2 46 1 
0 22 0 
- -2 40 4 
0 78 1 
1 95 0 
0 55 0 
0 77 0 
-1 78 1 
~--K-........... .. 
. .. -.-_ ...................... -- ..... . 
....... :- .. -
• .;'_..1 
.' ,' . 
.. ' 
." oi-~-D ____ ~~~ __________ ~~ 
o 2 4 • • 10 12 14 1. 11 20 22 24 2. 
TIme (weeks> 
Ganclclovlr group Acyclovir group 
- .... _ .. _---
FIGURE 2. Probability of developing CMV disease in acyclovir and 
ganciclovir groups. 
TABLE 5. Multivariate analysis of risk factors for CMV infection 
and CMV disease using Cox proportional hazards model 
Risk factor Relative risk 95% CI P 
CMV infection 
High dose acyclovir alone 3.31 (1.86. 5.90> <0.00001 
prophylaxis 
Donor-positive/recipient- 4.84 11.39, 16.86) 0.013 
negative status 
CMV disea.se 
High dose acyclovir alone 3.98 (1.52, 10.39) 0.0046 
prophylaxis 
Transfusion of > 30 U of 4.84 \ 1.23, 6.37) 0.014 
packed red cells 
Along with a 60% reduction in the incidence of CMV infec-
tion, early prophylaxis with ganciciovir resulted in a 68% 
reduction in CMV disease. Furthermore, only 2 ganciclovir 
group patients developed tissue invasive disease compared 
with 11 patients who received high dose acyclovir alone. The 
prophylactic efficacy of early ganciclovir was also supported 
by the finding that no patient developed pneumonia com-
pared with 5 patients in the acyclovir group. There W88 no 
difference in the rate of CMV viremia between tiIe·etudy 
groups. However, viremia was observed in only 5K of pa-
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TABLE 6. Multivariate analysis of risk facton for CMV infection 
stratified by reC1pient pretranBplant CMV status using Cox 
proportional hazards model 
Risk factor Relative risk 95% CI P 
Primary infection 
Donor seropositive 
FFP transfused (ill 
Secondary infection 
High dose acyclovir 
alone prophylaxis 
6.00 
1.04 
4.80 
(1.68, 21.48) 0.006 
(1.00, 1.07) 0.043 
(2.28, 10.11) <0.00001 
tients with tissue invasive disease. This is in contrast to 
previous reports in which viremia was associated with virtu-
ally all cases of CMV disease (22) and suggests that both 
antiviral agents may in fact influence the recovery rate of 
CMV from blood samples obtained during CMV disease. The 
multivariate analysis identified the use of high dose acyclovir 
alone and donor-seropositivelrecipient-seronegative combi-
nations as risk factors for development of both CMV infection 
and CMV disease. Additionally, transfusion of more that 30 U 
of packed red cells increased the risk for CMV disease but not 
infection. Although CMV-screened blood was not used rou-
tinely in our trial, this result is consistent with recent data 
from our center suggesting that blood transfusions increase 
the probability of CMV pneumonia during primary infection 
following liver transplantation (23). It is unclear how mul-
tiple blood transfusions act; possibly, they increase the CMV 
viral inoculum or somehow alter cellular immunity. 
CMV-related death was not seen in either group. However, 
CMV disease preceded death in 4 out of 5 (80%) acyclovir 
group patients compared with 1 out of 8 (13%) ganciclovir 
group patients. These results are in agreement with previous 
studies in which high mortality was observed when CMV 
disease preceded serious bacterial and fungal infections (24 l. 
In this trial, neither high dose acyclovir alone nor sequen-
tial ganciclovir-high dose acyclovir reduced the rate of pri-
mary infection, although infection was postponed by ganci-
dovir. Despite failure to reduce primary infection or CMV 
viral syndrome by ganciclovir. only 1 seronegative patient 
from the ganciclovir group developed tissue invasive disease, 
while there were 5 such patients from the acyclovir group. 
This reduction in severity of CMV disease during primary 
infection in the ganciclovir group may not have reached sig-
nificance because of small numbers. It may be related to 
delaying infection beyond the early posttransplant critical 
period, when immunosuppression requirements are greatest. 
The lack of effect of either prophylaxis regimen studied here 
in the prevention of primary infection is consistent with ob-
servations in lung transplant, pediatric liver recipients and 
heart recipients (25-27). In contrast, high dose oral acyclovir 
has been reported to be effective in preventing primary CMV 
infection in kidney transplant recipients. The disparity be-
tween these results may relate to basic differences in the 
spectrum and severity ofCMV disease in the different organ 
transplant populations, or to the varying immunosuppres-
sion drug regimens used (28--30). 
The significant risk factors for primary infection in the 
multivariate analysis were donor seropositive status and 
units of FFP transfused. It was particularly surprising that 
FFP, a virtually cell-free component, waa associated with a 
high risk of primary CMV infection. However, in a recent 
study, CMV DNA was isolated from plasma of AIDS patients, 
suggesting that plasma may also transmit CMV (31). 
The relationship between CMV infection and allograft re-
jection is complex. The majority of patients in this trial re-
ceived FK506. In our institution. FK506 has reduced the 
need for repeated steroid boluses and antilymphocytic agents 
such as OK.T3 to treat rejection (32). Despite a decrease in 
bacterial and fungal infections observed during our random-
ized FK506/CsA trial, the incidence of CMV disease was un-
changed, suggesting that other factors are perhaps more im-
portant in liver transplant recipients (32). The number of 
patients receiving CsA in our study was too small to assess 
whether differences in the rates of CMV infection were influ-
enced by the type of immunosuppression. Rejection was a 
borderline statistical risk factor for secondary CMV infection. 
However, early ganciclovir prophylaxis may have eliminated 
any statistical association between rejection and secondary 
infection. 
Both drugs regimens were well tolerated, with only a rare 
occurrence of hematologic and neurologic side effects. True 
bone marrow depression was observed in only 1 patient 
(1.5%) and this was easily reversed once ganciclovir was dis-
continued. The issue of drug absorption and dosing is an 
important factor when comparing our patients with other 
solid organ recipients; disturbances of gastrointestinal tract 
function and motility are frequent following liver transplan-
tation. The transplant operation itself, the type of biliary 
tract reconstruction, together with the common postoperative 
intra-abdominal problems exert an important effect on drug 
absorption. Whether administering acyclovir intravenous to 
assure bioavailability would have altered our findings re-
mains unknown. The incidence of CMV infection in our pa-
tients, however, was not affected by the type of biliary tract 
anastomosis. 
The incidence of infection after prophylaxis with high dose 
oral acyclovir alone was similar to previous reports of CMV 
infection from our institution when CMV prophylaxis was not 
given (33). Also, most cases of CMV infection and disease 
appeared during the period of ongoing acyclovir therapy. Fur-
thermore, a recent innovative trial conducted by Singh et a1. 
(34) comparing high dose acyclovir to "preemptive" ganciclo-
vir at the time of viral shedding demonstrated similar rates 
of infection in the acyclovir arm. Another study reported by 
Snydman et al. (35) noted a virtually identical infection and 
disease rate in their placebo patients. This raises serious 
doubt as to whether acyclovir has any effect by itself or fol-
lowing the early course of ganciclovir. The effectiveness of 2 
weeks of ganciclovir alone. however. remains to be studied. Of 
concern is the recent observation that ganciclovir for 1 week 
combined with human immunoglobulin was less effective 
than high dose acyclovir in a large randomized trial of organ 
transplant patients (predominantly renal transplant pa-
tients) at the University of Minnesota (36). 
In the setting of liver transplantation, this trial supports 
the use of an early, short course of intravenous ganciclovir to 
reduce CMV infection and CMV disease. It is unclear 
whether the subsequent use of high dose acyclovir contrib-
uted to the benefit observed. The decreased effectiveness of 
this protocol in the donor-seropositivelrecipient-seronegative 
population emphaaizea the need Cor new strategiu to prevent 
primary infection. 
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